Erdafitinib in Patients with FGFR- Altered Advanced or Metastatic Cholangiocarcinoma
Authors:
- Shubham PantSPShubham Pant
- Joon Oh ParkJPJoon Oh Park
- Wu-Chou SuWu-Chou Su
- Yohann LoriotYLYohann Loriot
- Omar CarranzaOCOmar Carranza
- Marcelo CorassaMCMarcelo Corassa
- Toshihiko DoiTDToshihiko Doi
- Shukui QinSQShukui Qin
- Josep TaberneroJTJosep Tabernero
- Hans PrenenHPHans Prenen
- Gunnar FolprechtGFGunnar Folprecht
- Helen WinterHWHelen Winter
Open Access
- 29 December 2025
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (6) , 1136-1144
Abstract
Purpose: Up to 20% of patients with cholangiocarcinoma (CCA) harbor FGFR gene aberrations. Erdafitinib is approved for pretreated, locally advanced/metastatic urothelial carcinoma with susceptible FGFR3 alterations. The present study evaluated the efficacy and safety of erdafitinib using a pooled analysis of patients with CCA from the RAGNAR and LUC2001 studies. Experimental Design: In RAGNAR (phase II, global, tumor-agnostic study) and LUC2001 (an open-label, multicenter, phase IIa study in Asian patients), patients with advanced solid tumors after ≥1 prior lines of therapy received once daily oral erdafitinib (8 mg/day with an option for pharmacodynamically guided up-titration to 9 mg). Patients were pooled for efficacy [objective response rate (ORR) per blinded independent review committee, duration of response (DOR), progression-free survival (PFS), and overall survival (OS)] and safety analyses. Results: At a median efficacy follow-up of 14.7 months in 78 erdafitinib-treated patients (RAGNAR: n = 66; LUC2001: n = 12), ORR was 55% [95% confidence interval (CI), 43.4–66.4]. The median time to response was 1.7 months; the median DOR, PFS, and OS were 6.9 (95% CI, 4.37–8.61), 8.5 (95% CI, 6.83–9.72), and 18.1 (95% CI, 13.40–24.28) months, respectively. The most common treatment-emergent adverse events (TEAE) were hyperphosphatemia (83%), stomatitis (72%), diarrhea (68%), dry mouth (51%), and palmar–plantar erythrodysesthesia (51%); 42% had serious TEAEs, and 12% had TEAEs leading to treatment discontinuation. Conclusions: Pooled analyses confirm the robust efficacy of erdafitinib in a diverse population of pretreated patients with advanced/metastatic CCA harboring prespecified FGFR alterations. These findings are consistent with previously observed efficacy of FGFR-targeted agents in patients with CCA.Keywords
All Related Versions
Funding Information
- Johnson & Johnson Innovative Medicine
This publication has 41 references indexed in Scilit:
- Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive CholangiocarcinomaCancer Discovery, 2017
- Systemic Therapy of CholangiocarcinomaVisceral Medicine, 2016
- Future directions in the treatment of cholangiocarcinomaBest Practice & Research Clinical Gastroenterology, 2015
- Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinomaHuman Pathology, 2014
- Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trialsAnnals of Oncology, 2013
- Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinomaHepatology, 2013
- Identification of Targetable FGFR Gene Fusions in Diverse CancersCancer Discovery, 2013
- Chemotherapy for cholangiocarcinoma: An updateWorld Journal of Gastrointestinal Oncology, 2013
- Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in CancerClinical Cancer Research, 2012
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010